These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 39144987)

  • 1. Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.
    Henríquez R; Muñoz-Barroso I
    Heliyon; 2024 Aug; 10(15):e34927. PubMed ID: 39144987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus like particle-based vaccines against emerging infectious disease viruses.
    Liu J; Dai S; Wang M; Hu Z; Wang H; Deng F
    Virol Sin; 2016 Aug; 31(4):279-87. PubMed ID: 27405928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like Particle Vaccines and Platforms for Vaccine Development.
    Kheirvari M; Liu H; Tumban E
    Viruses; 2023 May; 15(5):. PubMed ID: 37243195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
    Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
    J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-like particles as powerful vaccination strategy against human viruses.
    Hadj Hassine I; Ben M'hadheb M; Almalki MA; Gharbi J
    Rev Med Virol; 2024 Jan; 34(1):e2498. PubMed ID: 38116958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates.
    Collett S; Earnest L; Carrera Montoya J; Edeling MA; Yap A; Wong CY; Christiansen D; Roberts J; Mumford J; Lecouturier V; Pavot V; Marco S; Loi JK; Simmons C; Gulab SA; Mackenzie JM; Elbourne A; Ramsland PA; Cameron G; Hans D; Godfrey DI; Torresi J
    Front Microbiol; 2023; 14():1065609. PubMed ID: 37350788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
    Garg H; Sedano M; Plata G; Punke EB; Joshi A
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-like particle-based vaccines for animal viral infections.
    Crisci E; Bárcena J; Montoya M
    Inmunologia; 2013; 32(3):102-116. PubMed ID: 32287712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-like particles: potential veterinary vaccine immunogens.
    Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
    Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2.
    Hemmati F; Hemmati-Dinarvand M; Karimzade M; Rutkowska D; Eskandari MH; Khanizadeh S; Afsharifar A
    Biotechnol Lett; 2022 Jan; 44(1):45-57. PubMed ID: 34837582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platforms, advances, and technical challenges in virus-like particles-based vaccines.
    Gupta R; Arora K; Roy SS; Joseph A; Rastogi R; Arora NM; Kundu PK
    Front Immunol; 2023; 14():1123805. PubMed ID: 36845125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease.
    Wu XX; Yao HP; Wu NP; Gao HN; Wu HB; Jin CZ; Lu XY; Xie TS; Li LJ
    Cell Physiol Biochem; 2015; 37(5):1641-58. PubMed ID: 26535889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major findings and recent advances in virus-like particle (VLP)-based vaccines.
    Mohsen MO; Zha L; Cabral-Miranda G; Bachmann MF
    Semin Immunol; 2017 Dec; 34():123-132. PubMed ID: 28887001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
    Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
    Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.
    Nooraei S; Bahrulolum H; Hoseini ZS; Katalani C; Hajizade A; Easton AJ; Ahmadian G
    J Nanobiotechnology; 2021 Feb; 19(1):59. PubMed ID: 33632278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advancements in combination subunit vaccine development.
    Tan M; Jiang X
    Hum Vaccin Immunother; 2017 Jan; 13(1):180-185. PubMed ID: 27649319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.